- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04863872
- Original Trial
Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2) (PHT2)
Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia
Severe hypoglycemia is the most feared complication of medications used to lower blood glucose levels in patients with diabetes. Severe hypoglycemia, defined as plasma glucose low enough to require assistance, has been linked to poor health-related quality of life, emotional and interpersonal challenges, car accidents, serious falls, cardiovascular events, dementia, and death. Older adults with type 2 diabetes are particularly vulnerable to the complications of severe hypoglycemia. Each year, approximately 11% of patients with type 2 diabetes self-report severe hypoglycemia episodes. An estimated 14% of emergency hospitalizations of older Americans for adverse drug events implicate insulin and 11% implicate oral hypoglycemic agents. One in four diabetes-related hospital admissions is for hypoglycemia.
This study will compare two ways to reduce severe hypoglycemia in people with type 2 diabetes. The two methods to be compared are:
- Proactive care management. This will be a nurse outreach call which is similar to the usual care that people with type 2 diabetes get to reduce their risk of severe hypoglycemia, but given in advance rather than in response to a recent severe hypoglycemia event.
- The same proactive care management (nurse outreach call) plus enrollment in MyHC-T2D, a health education program aimed at improving awareness of hypoglycemia and preventing severe hypoglycemia. This program has been shown to reduce severe hypoglycemia in people with type 1 diabetes but has not been tested in persons with type 2.
Our hypothesis is that proactive care management plus MyHC-T2D will be more effective than proactive care management alone at preventing self-reported severe hypoglycemia in adults with type 2 diabetes at high risk for severe hypoglycemia. The primary outcome will be measured using surveys at the beginning of the study and 14-months later.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a two-arm, individually-randomized, comparative effectiveness study of two evidence-based approaches to preventing severe hypoglycemia. We will identify participants using Electronic Health Record (EHR) data. They will be identified for potential recruitment if they are age 18 and older, diagnosed with type 2 diabetes, receiving primary care at Kaiser Permanente Washington and have a current prescription for insulin or identified using an EHR-based risk stratification tool as being at intermediate to high risk for a severe hypoglycemia event. Within this population, we will recruit participants who either have impaired awareness of hypoglycemia or self-report a severe hypoglycemia event in the prior 12 months. Participants must be members of Kaiser Permanente Washington and identified by the study.
Following randomization, we will compare patients who receive proactive care management from nurses to patients receiving proactive care management plus MyHC-T2D, a structured educational intervention that reduces the frequency of severe hypoglycemia in individuals with type 1 diabetes. In both groups, we will use proactive care management to assess and provide evidence-based care for impaired awareness of hypoglycemia and other potential contributors to severe hypoglycemia risk.
Our primary outcome is participant-reported severe hypoglycemia, to capture all events, including those not involving clinical care. We will also examine biochemical measures of hypoglycemia measured using continuous glucose monitoring (CGM), participant-reported hypoglycemia awareness, fear of hypoglycemia, and emergency department visits and hospitalizations for severe hypoglycemia. We will conduct a process evaluation to assess the fidelity of implementation and clarify the causal pathway.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98101
- Kaiser Permanente Washington Health Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older
- Diagnosed with type 2 diabetes
- Receiving primary care at Kaiser Permanente Washington (KPWA)
- Enrollment in KPWA at baseline and planning to stay with a KPWA health plan for the next 6 months
- Current prescription for insulin or at intermediate to high risk for severe hypoglycemia episode using the hypoglycemia risk stratification tool developed by Karter et. al.
- History of severe hypoglycemia in the prior 12 months or impaired awareness of hypoglycemia
Exclusion Criteria:
- Inability to give informed consent
- Unable to speak or read English
- Inability or unwillingness to attend online or telephone educational sessions, follow up calls, or to complete outcome assessments
- Prior diagnosis of dementia, severe psychiatric conditions with psychosis, severe cognitive impairment
- Currently living in a nursing home or under hospice care
- Current use at baseline of Continuous Glucose Monitor
- Pregnant or planning to become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Proactive Care Management
Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
|
Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
|
|
Experimental: Proactive Care Management + MyHC-T2D education program
Participants will receive the same telephone nurse outreach call with follow up as clinically indicated as the comparator arm and will in in additional be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia.
The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
|
Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia.
The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported Severe Hypoglycemia
Time Frame: 14 months
|
Any self-reported severe hypoglycemia in prior 12 months
|
14 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James Ralston, MD, MPH, Kaiser Permanente Washington
Publications and helpful links
General Publications
- Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994 Jul;17(7):697-703. doi: 10.2337/diacare.17.7.697.
- Karter AJ, Warton EM, Lipska KJ, Ralston JD, Moffet HH, Jackson GG, Huang ES, Miller DR. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. JAMA Intern Med. 2017 Oct 1;177(10):1461-1470. doi: 10.1001/jamainternmed.2017.3844.
- Fitzgerald JT, Davis WK, Connell CM, Hess GE, Funnell MM, Hiss RG. Development and validation of the Diabetes Care Profile. Eval Health Prof. 1996 Jun;19(2):208-30. doi: 10.1177/016327879601900205.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IHS-2019C3-17889
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Hypoglycemia
-
Xeris PharmaceuticalsEmpiristat, Inc.CompletedType 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin HypoglycemiaUnited States, Canada, Austria
-
Xeris PharmaceuticalsSGS S.A.; Integrated Medical DevelopmentCompletedType 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin HypoglycemiaUnited States, Canada
-
EndoCell Therapeutics, Inc.RecruitingDiabetes Mellitus, Type 1 | Impaired Hypoglycemic Awareness | Severe HypoglycemiaChina
-
Vertex Pharmaceuticals IncorporatedRecruitingDiabetes Mellitus, Type 1 | Impaired Hypoglycemic Awareness | Severe HypoglycemiaUnited States, Norway, Italy, Canada, France, United Kingdom, Netherlands, Germany, Saudi Arabia, Switzerland
-
Cliniques universitaires Saint-Luc- Université...The Leona M. and Harry B. Helmsley Charitable TrustRecruitingType1diabetes | Severe HypoglycemiaBelgium
-
Nordsjaellands HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedType 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe HypoglycaemiaDenmark
-
Amylyx Pharmaceuticals Inc.AvailablePost-bariatric HypoglycemiaUnited States
-
HEIDEGGER CPAalborg UniversityCompletedHyperglycemia | Hypoglycemia | Critical Illness | Protein Deficiency | Energy Supply; Deficiency, SevereSwitzerland
-
Baylor Research InstituteRecruiting
-
MBX BiosciencesRecruitingPostbariatric HypoglycemiaUnited States
Clinical Trials on Proactive Care Management
-
Shen-Ing,LiuNational Science Council, TaiwanCompletedSuicide, AttemptedTaiwan
-
Johannes Gutenberg University MainzUnknown
-
Aerospace Center HospitalNot yet recruitingPseudomyxoma Peritonei | Postoperative Delirium (POD)China
-
VA Greater Los Angeles Healthcare SystemCompletedHeart Failure With Reduced Ejection FractionUnited States
-
University of AarhusCompletedOsteoarthritisDenmark
-
NovaResp Technologies IncCompleted
-
Ontario Clinical Oncology Group (OCOG)University Health Network, Toronto; Princess Margaret Hospital, CanadaCompleted
-
Leiden University Medical CenterActive, not recruitingChronic Disease | Multimorbidity | Psychosocial Problem | Complex PatientNetherlands
-
Yonghong LiEnrolling by invitationProstate Cancer (Adenocarcinoma)China
-
University of MichiganSt. Joseph Mercy Health SystemCompletedPeripheral Nervous System Diseases | Pain Management | Self ManagementUnited States